2023-08-07 16:15:14 ET
- Theravance Biopharma press release ( NASDAQ: TBPH ): Q2 GAAP EPS of -$0.28 misses by $0.07 .
- Revenue of $13.75M (+23.9% Y/Y) misses by $1.67M .
- Cash Position: Cash, cash equivalents and marketable securities totaled $167.5 million as of June 30, 2023.
- 2023 Financial Guidance
- Operating Expenses (excluding share-based compensation and one-time restructuring costs): The Company continues to expect full year 2023 R&D expense of $35 million to $45 million and SG&A expense of $45 million to $55 million.
- The Company reaffirms its expectation that it will generate non-GAAP profit in 2H 2023, subject to YUPELRI's increased net sales growth.
For further details see:
Theravance Biopharma GAAP EPS of -$0.28 misses by $0.07, revenue of $13.75M misses by $1.67M